{"id":245584,"date":"2026-10-17T21:07:27","date_gmt":"2026-10-18T02:07:27","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/10\/can-we-reverse-aging-first-human-trial-results"},"modified":"2026-10-17T21:07:27","modified_gmt":"2026-10-18T02:07:27","slug":"can-we-reverse-aging-first-human-trial-results","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/10\/can-we-reverse-aging-first-human-trial-results","title":{"rendered":"Can We Reverse Aging? First Human Trial Results"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/ki6VgGbYMJg?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>Three people going blind got one injection designed to make their old eye cells young again. Eight weeks later, two of them could see better. These are the first human results from age-reversal gene therapy.<\/p>\n<p>In this episode of Health Longevity Secrets, Robert Lufkin MD breaks down the first-in-human data for ER-100, Life Biosciences\u2019 epigenetic reprogramming therapy for glaucoma, presented October 8, 2026. You\u2019ll learn how the OSK (Yamanaka factor) genes reset old retinal cells, what the safety data showed, what a 4-decibel visual field gain really means, how the therapy guards against cancer, and why three patients with no placebo group is a first step, not proof.<\/p>\n<p>CHAPTERS:<br \/> 00:00 \u2014 Introduction: First Human Results of Age Reversal.<br \/> 00:28 \u2014 Recap: Human Age Reversal Has Begun.<br \/> 00:44 \u2014 Glaucoma: Why Lost Vision Can\u2019t Be Restored Today.<br \/> 00:59 \u2014 Harvard 2020: OSK Genes Restore Vision in Old Mice.<br \/> 01:29 \u2014 ER-100 Phase 1 Trial: First Human Results.<br \/> 02:05 \u2014 ER-100 Safety Data Through Day 56<br \/> 02:28 \u2014 2 of 3 Glaucoma Patients Improved Their Vision.<br \/> 02:48 \u2014 What a 4 dB Visual Field Gain Really Means.<br \/> 03:42 \u2014 Does Cellular Reprogramming Cause Cancer?<br \/> 04:17 \u2014 Will Age Reversal Arrive in Our Lifetime?<br \/> 04:40 \u2014 Beyond Glaucoma: Macular Degeneration and Other Diseases.<br \/> 04:59 \u2014 Honest Caveats: 3 Patients, No Placebo, Learning Effect.<br \/> 06:04 \u2014 The Takeaway: The Race to Reverse Aging.<\/p>\n<p>KEY TAKEAWAYS:<br \/> \u2022 ER-100 is the first therapy built to reverse cellular aging to be tested in people: 3 glaucoma patients, one eye injection at the lowest dose, plus doxycycline as the on-switch for 8 weeks.<br \/> \u2022 Safety was clean through day 56: no dose-limiting toxicities and no serious adverse events attributed to the gene therapy.<br \/> \u2022 2 of 3 patients improved on the Humphrey visual field test, with at least 28% of tested points improving by more than 4 dB (about 2.5x dimmer light detected).<br \/> \u2022 An independent safety board approved tripling the dose for the next patients.<br \/> \u2022 The therapy leaves out c-Myc, a known cancer gene, and has an off switch; patients will be followed until about 2032.<br \/> \u2022 Big caveats: 3 patients, no placebo, open-label, a noisy test with a known learning effect, and a company presentation rather than a peer-reviewed paper.<\/p>\n<p>STUDIES &amp; SOURCES MENTIONED:<br \/> \u2022 Life Biosciences \u2014 First-in-human data from the ongoing Phase 1 trial of ER-100 (Oct 8, 2026) \u2014 <a href=\"https:\/\/www.lifebiosciences.com\/life-\">https:\/\/www.lifebiosciences.com\/life\u2013<\/a>\u2026<br \/> \u2022 Lu et al., Nature 2020 \u2014 Reprogramming to recover youthful epigenetic information and restore vision \u2014 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33268\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33268<\/a>\u2026<br \/> \u2022 ClinicalTrials.gov NCT07290244 \u2014 Evaluating ER-100 for Safety in Optic Neuropathies \u2014 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT0\">https:\/\/clinicaltrials.gov\/study\/NCT0<\/a>\u2026<br \/> \u2022 Gillespie et al., Invest Ophthalmol Vis Sci 2003 \u2014 CIGTS visual field test-retest variability \u2014 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12766\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12766<\/a>\u2026<br \/> \u2022 Business Insider \u2014 Silicon Valley billionaires and cellular reprogramming (Oct 2026) \u2014 <a href=\"https:\/\/www.businessinsider.com\/billi\">https:\/\/www.businessinsider.com\/billi<\/a>\u2026<br \/> \u2022 Previous episode \u2014 Human Age Reversal Has Begun \u2014 \u2022 Human Age Reversal Has Begun.<\/p>\n<p>This video is for educational purposes only and is not medical advice.<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2026\/10\/can-we-reverse-aging-first-human-trial-results\">Continue reading \u201cCan We Reverse Aging? First Human Trial Results\u201d | &gt;<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Three people going blind got one injection designed to make their old eye cells young again. Eight weeks later, two of them could see better. These are the first human results from age-reversal gene therapy. In this episode of Health Longevity Secrets, Robert Lufkin MD breaks down the first-in-human data for ER-100, Life Biosciences\u2019 epigenetic [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,32,412,269],"tags":[],"class_list":["post-245584","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-education","category-genetics","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=245584"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245584\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=245584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=245584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=245584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}